Radiation Oncology Journal

  • 제30권4호
  • /
  • Pages.182-188
  • /
  • 2012
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy

  • Kim, Young Suk (Department of Radiation Oncology, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Lee, Chang Geol (Department of Radiation Oncology, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Kim, Kyung Hwan (Department of Radiation Oncology, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Kim, Taehyung (Department of Radiation Oncology, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Lee, Joohwan (Department of Radiation Oncology, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Cho, Yona (Department of Radiation Oncology, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Koom, Woong Sub (Department of Radiation Oncology, Yonsei University Health System, Yonsei University College of Medicine)
  • 투고 : 2012.09.11
  • 심사 : 2012.10.22
  • 발행 : 2012.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: For recurrent esophageal cancer after primary definitive radiotherapy, no general treatment guidelines are available. We evaluated the toxicities and clinical outcomes of re-irradiation (re-RT) for recurrent esophageal cancer. Materials and Methods: We analyzed 10 patients with recurrent esophageal cancer treated with re-RT after primary definitive radiotherapy. The median time interval between primary radiotherapy and re-RT was 15.6 months (range, 4.8 to 36.4 months). The total dose of primary radiotherapy was a median of 50.4 Gy (range, 50.4 to 63.0 Gy). The total dose of re-RT was a median of 46.5 Gy (range, 44.0 to 50.4 Gy). Results: The median follow-up period was 4.9 months (range, 2.6 to 11.4 months). The tumor response at 3 months after the end of re-RT was complete response (n = 2), partial response (n = 1), stable disease (n = 2), and progressive disease (n = 5). Grade 5 tracheoesophageal fistula developed in three patients. The time interval between primary radiotherapy and re-RT was less than 12 months in two of these three patients. Late toxicities included grade 1 dysphagia (n = 1). Conclusion: Re-RT of recurrent esophageal cancer after primary radiotherapy can cause severe toxicity.

키워드

과제정보

연구 과제 주관 기관 : Ministry for Health, Welfare & Family Affairs

참고문헌

  1. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8. https://doi.org/10.1056/NEJM199206113262403
  2. Araujo CM, Souhami L, Gil RA, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 1991;67:2258-61. https://doi.org/10.1002/1097-0142(19910501)67:9<2258::AID-CNCR2820670908>3.0.CO;2-G
  3. Tachimori Y. Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2009;57:71-8 https://doi.org/10.1007/s11748-008-0337-5
  4. Fakhrian K, Gamisch N, Schuster T, Thamm R, Molls M, Geinitz H. Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol 2012;188:136-42. https://doi.org/10.1007/s00066-011-0023-x
  5. Yano M, Takachi K, Doki Y, et al. Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus 2006;19:73-7. https://doi.org/10.1111/j.1442-2050.2006.00543.x
  6. Shioyama Y, Nakamura K, Ohga S, et al. Radiation therapy for recurrent esophageal cancer after surgery: clinical results andprognostic factors. Jpn J Clin Oncol 2007;37:918-23. https://doi.org/10.1093/jjco/hym138
  7. Morita M, Kumashiro R, Hisamatsu Y, et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroenterol 2011;46:1284-91. https://doi.org/10.1007/s00535-011-0448-0
  8. Yano T, Muto M, Hattori S, et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 2008;40:717-21. https://doi.org/10.1055/s-2008-1077480
  9. Hattori S, Muto M, Ohtsu A, et al. EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc 2003;58:65-70. https://doi.org/10.1067/mge.2003.306
  10. Harms W, Krempien R, Grehn C, Berns C, Hensley FW, Debus J. Daytime pulsed dose rate brachytherapy as a new treatment option for previously irradiated patients with recurrent oesophageal cancer. Br J Radiol 2005;78:236-41. https://doi.org/10.1259/bjr/51982166
  11. Yamaguchi S, Ohguri T, Imada H, et al. Multimodal approaches including three-dimensional conformal re-irradiation for recurrent or persistent esophageal cancer: preliminary results. J Radiat Res 2011;52:812-20. https://doi.org/10.1269/jrr.11066
  12. Nonoshita T, Sasaki T, Hirata H, et al. High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer. Radiat Med 2007;25:373-7. https://doi.org/10.1007/s11604-007-0152-4
  13. Teli MA, Mushood GN, Zargar SA, Andrabi WH. Comparative evaluation between re-irradiation and demand endoscopic dilatation vs endoscopic dilatation alone in patients with recurrent/reactivated residual in-field esophageal malignancies. J Cancer Res Ther 2008;4:121-5. https://doi.org/10.4103/0973-1482.43140
  14. Russo JK, Rosen L. TomoTherapy stereotactic body radiation therapy (SBRT) for the salvage treatment of locally recurrent esophageal adenocarcinoma following trimodality therapy: a case report. Tumori 2011;97:406-10.
  15. Sharma V, Mahantshetty U, Dinshaw KA, Deshpande R, Sharma S. Palliation of advanced/recurrent esophageal carcinoma with high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2002;52:310-5. https://doi.org/10.1016/S0360-3016(01)01822-3

피인용 문헌

  1. The Efficacy and Safety of Re-Irradiation for 18 Patients with Malignant Tumor vol.2, pp.4, 2012, https://doi.org/10.12677/acrpo.2013.24005
  2. An Unusual Course of Metastatic Gastroesophageal Cancer vol.2015, pp.None, 2012, https://doi.org/10.1155/2015/941508
  3. Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair vol.8, pp.None, 2012, https://doi.org/10.2147/ott.s76958
  4. High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer : Experience from a large single-center cohort vol.192, pp.7, 2016, https://doi.org/10.1007/s00066-016-0979-7
  5. Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer vol.13, pp.3, 2012, https://doi.org/10.3892/ol.2017.5605
  6. Re-irradiation of locoregional esophageal cancer recurrence following definitive chemoradiotherapy: A report of 6 cases vol.7, pp.4, 2012, https://doi.org/10.3892/mco.2017.1384
  7. Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study vol.12, pp.None, 2012, https://doi.org/10.1186/s13014-017-0882-0
  8. Clinical application of oral meglumine diatrizoate esophagogram in screening esophageal fistula during radiotherapy for esophageal cancer vol.97, pp.18, 2012, https://doi.org/10.1097/md.0000000000010668
  9. Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy : Study protocol for a prospective multi-center phase II trial vol.98, pp.26, 2012, https://doi.org/10.1097/md.0000000000016176
  10. Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy vol.14, pp.1, 2019, https://doi.org/10.1186/s13014-019-1402-1
  11. Risk Factors for Esophageal Fistula in Esophageal Cancer Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis vol.43, pp.1, 2012, https://doi.org/10.1159/000503754
  12. Risk Factors Associated with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma vol.11, pp.12, 2012, https://doi.org/10.7150/jca.39033
  13. Definitive re-irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status vol.13, pp.1, 2012, https://doi.org/10.3892/mco.2020.2044
  14. Assessing Outcomes of Patients Treated With Re-Irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction vol.15, pp.6, 2012, https://doi.org/10.1016/j.jtho.2020.01.024
  15. Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis vol.15, pp.1, 2012, https://doi.org/10.1186/s13014-020-01685-2
  16. Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees vol.11, pp.None, 2012, https://doi.org/10.3389/fonc.2021.748331
  17. A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11) vol.26, pp.6, 2012, https://doi.org/10.1002/onco.13668
  18. Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma vol.5, pp.4, 2021, https://doi.org/10.1002/ags3.12448
  19. A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy vol.16, pp.1, 2012, https://doi.org/10.1186/s13014-021-01828-z